Acta Clinica Belgica

International Journal of Clinical and Laboratory Medicine

Volume 70, 2015 - Issue 1

155

Views

CrossRef citations to date

Altmetric

Original Papers

Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey

Y. BeguinAvenue de l’Hopital 1, Liège, BelgiumCorrespondence[email protected]

D. SelleslagAZ Sint-Jan, Brugge-Oostende, Belgium

S. MeersAZ KLINA, Brasschaat, Belgium

C. GrauxCHU Dinant-Godinne UCL Namur Godinne (Yvoir), Belgium

G. BriesAZ Turnhout, Belgium

D. DeerenHematology-Medical Oncology H.-Hartziekenhuis Roeselare-Menen vzw, Belgium

I. VrelustUZA Edegem, Belgium

C. RavoetCentres hospitaliers JolimontHaine-Saint-Paul, Belgium

K. TheunissenVirga JesseHasselt, Belgium

V. VoelterCelgene International, Boudry, Switzerland

H. PotierAvenue de l’Hopital 1, Liège, Belgium

F. TrullemansDepartement Oncologie/Hematologie, UZ Brussel, Belgium

L. NoensGhent University Hospital, Belgium

P. MineurGrand Hopital de Charleroi (GHdC), Belgium

show all

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (5)

Ken Hasegawa, Andrew H Wei, Guillermo Garcia-Manero, Naval G Daver, Nishanthan Rajakumaraswamy, Shahed Iqbal, Rebecca J Chan, Hao Hu, Preston Tse, Jiajun Yan, Michael J Zoratti, Feng Xie & David A Sallman. (2023) Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. Clinical Lymphoma Myeloma and Leukemia 23:2, pages 127-137.
Crossref

Emilia Scalzulli, Matteo Molica, Danilo Alunni Fegatelli, Gioia Colafigli, Lorenzo Rizzo, Marco Mancini, Fabio Efficace, Roberto Latagliata, Robin Foà & Massimo Breccia. (2019) Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. Annals of Hematology 98:8, pages 1919-1925.
Crossref

Grzegorz Helbig, Karolina Chromik, Krzysztof Woźniczka, Anna J. Kopińska, Kinga Boral, Martyna Dworaczek, Anna Koclęga, Anna Armatys, Marta Panz-Klapuch & Mirosław Markiewicz. (2019) Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia. Pathology & Oncology Research 25:3, pages 1175-1180.
Crossref

Jürgen Wehmeyer, Matthias Zaiss, Christoph Losem, Stephan Schmitz, Beate Niemeier, Johanna Harde, Carla Verena Hannig, Hanns-Detlev Harich, Judith Müller, Martine Klausmann, Hans Werner Tessen & Karin Potthoff. (2018) Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study). European Journal of Haematology 101:6, pages 766-773.
Crossref

Vasiliki Pappa, Achilles Anagnostopoulos, Eleni Bouronikou, Evangelos Briasoulis, Ioannis Kotsianidis, Maria Pagoni, Panagiotis Zikos, Konstantinos Tsionos, Nora Viniou, John Meletis, Helen Papadaki, Anna Kioumi, Athanasios Galanopoulos, Elisavet-Christine Vervessou, Elias Poulakidas, Panagiotis Karmas, Kiki Karvounis & Argiris Symeonidis. (2016) A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece. International Journal of Hematology 105:2, pages 184-195.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey

Articles from other publishers (5)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey

Citations (5)

Articles from other publishers (5)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date